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Abstract  
Background. The prion protein-encoding gene (PRNP) is one of the major determinants 
for scrapie occurrence in sheep and goats. However, its effect on bovine spongiform 
encephalopathy (BSE) transmission to goats is not clear.  
Methods. Goats harboring wild type (WT), R/Q211 or Q/K222 PRNP genotypes were 
orally inoculated with a goat-BSE isolate to assess their relative susceptibility to BSE 
infection. Goats were culled at different time points during the incubation period and 
after the onset of clinical signs, and their brains as well as several peripheral tissues 
were analyzed for the accumulation of pathological prion protein (PrPSc) and prion 
infectivity by mouse bioassay.  
Results. R/Q211 goats displayed delayed clinical signs compared to WT goats. PrPSc was 
detected only in brain whereas infectivity was present in peripheral tissues too. In 
contrast, none of the Q/K222 goats showed any evidence of clinical prion disease. No 
PrPSc accumulation was observed in their brains or peripheral tissues but very low 
infectivity was detected in some tissues after very long post-inoculation times (44-45 
months).  
Conclusions. These results demonstrate that transmission of goat-BSE is genotype 
dependent and highlight the pivotal protective effect of the K222 PRNP variant in the 
oral susceptibility of goats to BSE. 
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INTRODUCTION  
Bovine spongiform encephalopathy (BSE) is a fatal neurodegenerative disease, 
belonging to the group of prion diseases or transmissible spongiform encephalopathies 
(TSEs). TSEs are characterized by the post-translational conversion of a normal cellular 
prion protein (PrPC, which is encoded by the prion protein-encoding gene PRNP) into 
an abnormal isoform (PrPSc) which accumulates in the tissues of infected humans and 
animals [1].  
Although it was firstly recognized as a cattle prion disease [2], the BSE agent has 
demonstrated a high capacity to cross species barriers, spreading  to humans, with the 
emergence of variant Creutzfeldt-Jakob disease (vCJD) [3, 4], cats and a variety of zoo 
animals during the BSE epidemic of 1980s [5]. Sheep and goats can be experimentally 
infected with this TSE too [6-8]. Moreover, two BSE “natural” cases have been reported 
in goats [9, 10]. 
Scrapie is a TSE affecting small ruminants all around the world. Its occurrence is 
strongly modulated by the prion protein-encoding gene (PRNP) and for goats, several 
PRNP polymorphisms have been linked with lower risk of developing classical scrapie: 
I/M142, N/S146 or N/D146, R/Q211 and Q/K222. Among them, the K222 PRNP variant 
yielded the most promising results, being associated with resistance to scrapie not only 
in epidemiological studies [11-18] but also in experimental inoculations in goats [19, 
20] and transgenic mice [21]. 
In contrast, little is known about the factors determining the susceptibility of goats to 
BSE although  prolonged incubation times in BSE-infected goats were associated with 
the I/M142 polymorphism [7]. More recently, we showed that transgenic mice expressing 
the K222 PRNP variant are resistant to cattle-BSE but not to sheep or goat-BSE [21].  
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In the present work, we studied the effect of certain PRNP genotypes in the oral 
transmission of goat-BSE agent to goats. For that purpose, WT, R/Q211 and Q/K222 goats 
were orally challenged with a goat-BSE isolate and their brain and some peripheral 
tissues were analyzed for the presence of either the accumulation of PrPSc by 
immunohistochemistry (IHC) or the presence of PrPres and prion infectivity by Western-
blot (WB) and mouse bioassay, respectively. 
MATERIALS AND METHODS 
Ethics statements  
Animal experiments were carried out in strict compliance with the recommendations of 
the Code for Methods and Welfare Considerations in Behavioral Research with Animals 
(Directive 86/609EC). The challenge experiments in goats described in this manuscript 
were approved by the competent authority of the Federal State of Mecklenburg-Western 
Pommerania, Germany (Permit Number: 7221.3-2.5-001/05).  Experiments in mice 
were carried out in CISA-INIA (Madrid) and authorized by the Committee on the Ethics 
of Animal Experiments (CEEA) of the Spanish Instituto Nacional de Investigación y 
Tecnología Agraria y Alimentaria (INIA); Permit Number: CEEA2009/003. 
Goat-BSE oral transmissions to goats  
Alpine-Saanen cross breed goats used in these transmission experiments were obtained 
by natural mating and sequenced as previously described [7]. At six to seven months of 
age goats harboring WT (R211Q222/RQ), R/Q211 or Q/K222 genotypes received a total 
dose of approximately 1g brain equivalent from BSE first-passaged in goat. This goat-
BSE material (gBSE-P12) was obtained by pooling brainstems from three WT goats 
experimentally inoculated with a mixture of four cattle-BSE field cases [6, 7]. Inoculum 
was orally administered at 1:5 (w/v) dilution in sterile 0.9 NaCl and each goat got 5ml 
of pooled goat brain homogenate. Goats were regularly monitored for the presence of 
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clinical signs typical of BSE (i.e. neurological disorders like abnormalities in sensation 
and movement). Goats were euthanatized at clinical stage or at scheduled times (Table 
1) using Ketaminhydrochlorid (10-15 mg/kg) and Xylazinhydrochlorid for anesthesia 
followed by euthanasia with T61 (4-6ml/50 kg body weight). During necropsy, a set of 
tissues was collected under TSE sterile conditions (among others brain, lymph node 
poplitealis, psoas major and retractor bulbi muscles) and harvested at -80ºC. A part of 
each sample was immediately fixed in neutral-buffered 10% formalin (4% 
formaldehyde). Subsequently these samples were treated for 1 h with 98% formic acid 
and rinsed in tap water for 40 min before dehydration and embedding in paraffin. After 
rehydration, 3 µm-thick brain slices were stained with hematoxylin and eosin (HE) and 
a histopathological examination was applied. For detecting PrPSc deposits, 
immunohistochemistry (IHC) analysis were performed as previously described [22], 
using 6C2 monoclonal antibody (mAb) (Central Veterinary Institute of Wageningen 
UR, Lelystad, Netherlands) and F99 mAb (VMRD, Pullman, USA). Shortly the sections 
were pretreated by an incubation with 98% formic acid (15 min), followed by 
autoclaving in citrate buffer for 20 min at 121°C. The endogenous peroxidase was 
inhibited by using 3% H2O2 in methanol for 30 min. The primary antibodies were 
diluted in goat serum, the 6C2 depending on the charge from 1:50 up to 1:150, the F99 
1:4000 and incubated for 2 h at room temperature. Negative control sections were 
treated with goat serum alone. As a secondary antibody we used the EnVision™ reagent 
(Dako, Hamburg, Germany) containing a peroxidase-conjugated polymer backbone. 
Incubation time on these sections was 30 min at room temperature. The slides were 
finally developed in diaminobenzidine tetrahydrochloride (Fluka, Steinheim, Germany) 
and counterstained with Mayer’s haematoxylin. All sections were examined by light 
microscopy. 
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Another part of each sample was homogenized as 10% (w/v) in sterile 0.9 NaCl for both 
determining the presence of PrPres by phosphotungstic acid Western-blot (PTA-WB) 
and/or standard Western-blot (WB), and studying the prion infectivity by mouse 
bioassay (see below). For TSE discriminatory testing PTA-WB of the brain stem 
samples  were performed by using the mabs L42 and P4 while Sha31 mAb [23] was 
employed in WB analysis following previously published procedures[22, 24, 25]. 
Mouse bioassay 
The sensitivity of BoPrP-Tg110 mice expressing the bovine-PrPC [26] and GowtPrP-
Tg501 mice expressing the goat-PrPC [21] for detecting goat-BSE prion infection was 
determined in a first experiment. BoPrP-Tg110 mice were selected for detecting the 
prion infectivity in goat tissues because of its higher sensitivity to goat-BSE prion 
infection than GowtPrP-Tg501 mice (Table S1 and Figure S1).  Groups of 6-9 
individually identified (six to seven weeks old) BoPrP-Tg110 mice were anesthetized 
with isoflurane and intracerebrally inoculated with 20 µl of the inocula (10% goat tissue 
homogenate) in the right parietal lobe using a 25 gauge disposable hypodermic needle. 
Mice were examined biweekly for the development of neurological signs of the prion 
disease and humanely euthanized by cervical dislocation when progression of the 
disease was evident or at the end of the study: 650 days post-inoculation (dpi) (Table 2). 
A mouse was considered positive for neurological disease when it showed two or three 
out of the 10 signs of neurological dysfunction previously described [27, 28]. Definitive 
diagnosis was made on observation of one confirmatory sign of prion disease (ataxia, 
generalized tremor, loss of righting reflex, limb paralysis, extensive pilo-erection or 
sustained hunched posture) and animals were culled at this point. Once euthanized, 
brain was removed and harvested at -20ºC for determining the presence of PrPres by 
Western-blot using Sha31 mAb, as previously described [25]. Survival time and attack 
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rate were calculated for each inoculum. Survival time was expressed as the mean of the 
survival dpi of all the mice scored positive for brain PrPres, with its correspondent 
standard error of the mean. Attack rate was determined as the proportion of mice scored 
positive for brain PrPres from all the inoculated mice. Mice that died due to intercurrent 
diseases were excluded from the study. The criteria for exclusion were as follow: i) 
animals that died before the first animal scored as positive for brain PrPres within the 
group of mice inoculated with the same inocula; ii) animals that died before 650 dpi 
when no positive mice were found in the group.   
The relative infectivity in the different goat tissues was calculated as a function of the 
survival times observed after their inoculation in BoPrP-Tg110 mice. For that purpose, 
the goat-BSE isolate formerly used in goat oral inoculations (gBSE-P12) [6, 7] was  
titrated by ten-fold serial dilution inoculation in BoPrP-Tg110 mice and its infectious 
dose (ID) was subsequently assessed by the Reed-Muench method [29] (Table S1). 
From these data, a standard dose response curve was established and the relative 
infectivity of each tissue was extrapolated by comparing their transmission results with 
those obtained in the goat-BSE (gBSE-P12) titration (Figure S1). 
 
RESULTS 
To study the influence of PRNP polymorphisms in the susceptibility of goats to BSE, 
goats harboring wild type (WT), R/Q211 or Q/K 222 PRNP genotypes were orally 
inoculated with a goat-BSE isolate (gBSE-P12) [6, 7] and monitored for the 
development of prion disease. Goats were euthanized at clinical stage or at scheduled 
time points during the incubation period to follow neurological lesions, PrPSc deposition 
and prion infectivity in brain and/or peripheral tissues. 
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PrPSc accumulation in BSE orally inoculated goats 
None of the WT goats killed at 6 or 12 months post-inoculation (mpi) exhibited any 
signs associated with BSE disease in the brain or the peripheral tissues examined here, 
neither by histopathology, and immunohistochemistry (IHC) nor by Western-blot (WB) 
and/or phosphotungstic acid Western-blot (PTA-WB) (Table 1). Clinical signs of the 
disease were first observed in a WT goat (ZG01) at 24 mpi (Table 1). This animal 
showed pathological alterations and accumulation of PrPSc in the brain stem as 
demonstrated by hematoxylin and eosin (HE) and IHC. WB (Figure 1) and PTA-WB 
confirmed the presence of BSE derived PrPres in this goat brain. However, in the 
popliteal lymph node (LN), retractor bulbi muscle or psoas major muscle all the applied 
methods failed to detect any amount of PrPSc (Table 1). 
In contrast to WT goats, WB, IHC and HE analysis of one of the R/Q211 goats, killed at 
24 mpi, revealed the absence of PrPSc deposits and neurodegenerative alterations in its 
brain (Table 1). However, three R/Q211 goats reached the clinical phase of BSE disease 
at 33 mpi (ZG28), 34 mpi (ZG05) or 36 mpi (ZG20) (Table 1) associated with clear 
spongiform encephalopathy and accumulation of PrPSc as shown in IHC. Additionally, 
all three R/Q211 goats (33-36 mpi) were scored PrPres positive in their brains by WB 
(Figure 1) and PTA-WB. As described for the WT goat, neither the muscles nor the 
popliteal LN revealed any signs of PrPSc by IHC or WB. 
None of the Q/K222 goats, which were killed at 24, 44 and 45 mpi, showed any evidence 
of prion disease (Table 1). These goats were scored as PrPres negative for all of their 
analized tissues by IHC, PTA-WB and/or WB (Table 1). 
WB analysis of the brain PrPSc in both WT and R/Q211 infected goats showed a typical 
BSE PrPSc banding pattern characterized by a 19-kDa aglycosyl band and prominent 
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diglycosylated species. The glycoprofiles were indistinguishable from those produced 
by the goat-BSE isolate originally used for goat challenges (gBSE-P12) (Figure 1). 
Infectivity in tissues from BSE-infected goats 
PrPSc is a specific and widely used TSE marker but its sensitivity can be lower than 
infectivity measures by mouse bioassay. Therefore, PrPSc negative goat tissues were 
inoculated in a very sensitive mouse model (BoPrP-Tg110) to evaluate the presence of 
prion infectivity (Table 2). 
No prion infectivity was detected in any tissue from WT goats killed at 6 or 12 mpi. 
When their brains and peripheral tissues homogenates were inoculated into BoPrP-
Tg110 mice, none of the mice succumbed to a prion disease; they were euthanized at 
650 dpi showing neither clinical signs nor PrPres in their brains by WB. Prion infectivity 
was detected in the brain from the WT goat killed at 24 mpi (ZG01 goat). After its 
inoculation, BoPrP-Tg110 mice showed 100% attack rates and short survival times 
(261±20 dpi) (Table 2), thus corresponding to a high infectious titer (>5 x 106 ID/g). 
Interestingly, BoPrP-Tg110 mice also succumbed to the inoculation of PrPSc negative 
popliteal LN, psoas major muscle and retractor bulbi muscle homogenates from this 
goat, displaying longer survival times and lower attack rates than those obtained with 
the brain homogenate (Table2). At this 24 mpi stage, no infectivity was detected in 
brain homogenate from R/Q211 goat (ZG13) (Table2). However, 100% BoPrP-Tg110 
mice succumbed to the inoculation of the pooled brain homogenates from ZG28, ZG05 
and ZG20 R/Q211 goats killed at 33-36 mpi. These mice showed similar survival times 
(258±15 dpi) to those previously obtained from the inoculation of the ZG01 WT goat 
brain and therefore, their infectious titers was comparable (>5 x 106 ID/g in both cases). 
Similarly to WT goat, R/Q211 goats also displayed prion infectivity in their PrPSc 
negative peripheral tissues. Pooled homogenates from popliteal LN, psoas major muscle 
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and retractor bulbi muscle infected BoPrP-Tg110 mice with higher attack rates and 
lower survival times than peripheral tissues from ZG01 WT goat (Table2). 
With regard to the Q/K222 goat tissues, only the brain from one goat killed at 45 mpi 
(ZG11) showed low level of infectivity. This was not the case in the other Q/K222 goat 
killed at 44 mpi (ZG25). 100% of the BoPrP-Tg110 mice succumbed to the brain 
inoculation from goat ZG11 although with considerably longer survival times (400±50 
dpi) than those obtained with brains from WT (261±20 dpi) and R/Q211 (258±15 dpi) 
goats. Traces of infectivity were also detected in PrPSc negative muscle psoas major 
from both Q/K222 goats, producing very low attack rate (1/6) and very long survival 
times (550 and 522 dpi, respectively) in BoPrP-Tg110 mice. 
In all cases, brain WB PrPres patterns from infected BoPrP-Tg110 mice were similar to 
that observed in the original goat-BSE isolate [6, 7] as well as to those seen in goat 
tissue homogenates, independently of the goat PRNP genotype (WT, R/Q211 or Q/K222) 
or the inoculated tissue (Figure 2).  
DISCUSSION 
In this study, we analyzed the effect of the prion protein-encoding gene (PRNP) in the 
transmission of BSE to goats. For that purpose, goats harboring different PRNP 
genotypes (WT, R/Q211 and Q/K222) were orally inoculated with a goat-BSE isolate, 
monitored for the development of clinical signs and culled at different time points. A 
panel of tissue samples was collected and studied for both the presence of PrPSc and 
infectivity by mouse bioassay.  
WT goats developed first clinical signs of TSE at 24 months after inoculation (mpi). 
Signs were consistent to previous BSE inoculations in sheep and goats [30, 31]. PrPSc 
deposits in the brain and neurodegenerative lesions were also in agreement with those 
formerly observed in BSE inoculated sheep and goats[31-33], being mainly detected at 
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the level of the obex. Additionally prion infectivity was also present in muscles and LN 
tissues as detected by mouse bioassay although with smaller titers than in brain. These 
results are consistent with the PrPSc spread from central nervous system (CNS) to 
peripheral tissues proposed in BSE oral transmissions in sheep and cattle [34, 35].  
R/Q211 goats firstly developed the BSE disease after 33 mpi. Prion infectivity in R/Q211 
goats was higher in brain than in peripheral tissues, well in agreement with WT goat 
results. Interestingly, for the R/Q211 goats the onset of the disease was delayed by 9 to 
12 months suggesting a genotype dependent transmission of BSE to goats in which the 
Q211 PRNP polymorphic variant might have an effect on incubation period but not 
susceptibility. Therefore, R/Q211 polymorphism could be associated with low resistance 
against goat-BSE, contrasting the high resistance to scrapie associated to this 
polymorphism in field [14, 18] and experimental [20] studies of goats. These 
differential results in the association of the Q211 PRNP variant with TSEs transmission 
is likely to be linked to the prion strain as a determinant factor for TSEs occurrence 
[36]. 
In contrast to the susceptibility of WT and R/Q211 goats to goat-BSE, none of the Q/K222 
goats examined here displayed any evidence of disease. Neither clinical signs nor PrPres 
were observed in any of these Q/K222 goats; histopathological analysis did not reveal 
any PrPSc deposits or neurological lesions. However, very low infectivity was detected 
in the brain from only one of the two Q/K222 goats euthanized at 44-45mpi. Traces of 
infectivity were also detected in psoas major muscles from both goats, thus suggesting 
that K222 PRNP variant drastically decreases the susceptibility of goats to goat-BSE. 
Remarkably, our group described that transgenic mice expressing the goat K222-PrPC 
variant are 100% susceptible to the intracerebral transmission of goat-BSE, displaying 
similar survival times than goat wt-PrP transgenic mice [21]. This result suggests that 
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the K222-PrPC variant is as able to replicate the goat adapted BSE agent as the goat WT-
PrPC. Hence, the resistance to goat-BSE might not be an intrinsic molecular property of 
K222-PrPC variant and the low susceptibility of Q/K222 goats against oral infection with 
goat-BSE might be additionally influenced by other factors than the host PRNP 
genotype.  
A plausible reason for the discrepancy between the results of goat-BSE transmissions to 
Q/K222 goats and K222-Tg516 mice could be the route of infection. Intracerebral 
inoculation (performed for transmission studies in Tg mice) provides the best route for 
prion replication since the inoculum is directly placed in the target tissue. Whereas by 
oral transmission (used for goat inoculation) prions must overcome several barriers 
prior to reach the target tissues: i) crossing the mucosal barrier, ii) amplification in gut-
associated lymphoid tissues, iii) lymphatic/haematogenic dissemination, iv) 
neuroinvasion via the peripheral nervous system (PNS) v) to finally  reach the CNS 
[30]. One or more of these steps might be affected in some way by the PRNP genotype, 
thus modulating the BSE capacity to replicate and/or spread through the organism. In 
line with this view, some authors have proposed that the ability of peripherally injected 
prions to replicate in extra neural tissues such as Peyer’s patches in the intestinal tract, 
spleen, tonsils, appendix or lymph nodes may be critical for prions to persist in the host 
before spreading to the PNS and then  to the CNS [37]. Lymphotropism seems to play 
an important role in prion infection. While BSE-PrPSc in cattle remained mainly 
distributed through the CNS and the vegetative nervous system [22, 34], the BSE agent 
becomes lymphotropic in sheep and goats with PrPSc accumulation in several lymphoid 
tissues [8, 38, 39]. BSE orally infected sheep showed PrPSc replication in lymphoid 
tissues such as tonsil and ileal Peyer’s patches before the infection of some areas of the 
ENS [40, 41]. On this basis, we hypothesize that the resistance of Q/K222 goats to oral 
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goat-BSE infection could be linked to a lower capability of goat-BSE to convert K222-
PrPC in peripheral organs. Lower levels of expression of K222-PrPC together with a 
regional variability of the K222-PrPC isoforms in these organs of primary transmission 
might not be ruled out [42].  
Discrepancies in prion transmission efficiency linked to the inoculation route were 
previously described in R/H154, R/Q211 or Q/K222 goats which were completely resistant 
to scrapie inoculation by oral route but susceptible by IC route [20]. Interestingly, while 
100% of the R/H154 and R/Q211 goats succumbed to the scrapie IC inoculation, only few 
Q/K222 goats developed the disease and with 4 to 5 times prolonged incubation periods 
than WT goats; supporting the view that the K222 variant renders goats less susceptible 
to scrapie infection than the Q211 variant. This statement might be extended to BSE 
infection too, as supported by transmission experiments presented here. Moreover, these 
results together with data collected from numerous experimental [19-21, 43] and 
epidemiological studies [11-18] indicate the low susceptibility of Q/K222 polymorphism 
to prion infection.  
We recently described that K222 PRNP variant interferes with the WT allele replication 
of the scrapie agent, thus resulting in prolonged incubation times and/or lower attack 
rates in heterozygous Q/K222 Tg mice compared to goat wt-PrP Tg mice [21]. In the 
present work, heterozygous Q/K222 goats were considerably less susceptible to the 
transmission of goat-BSE than WT goats, indicating that the K222 PRNP variant would 
protect also against goat-BSE oral infection. Since homozygous K/K222 goats were not 
challenged in this study, we cannot conclude on the level of resistance provided by K222 
PRNP variant and its ability to replicate goat-BSE.  
In summary, the results presented in this study demonstrate a genotype dependent 
transmission of the goat-BSE agent to goats where the K222 PRNP variant plays a 
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determinant role. The protective effect provided by the K222 PRNP variant against both 
goat-BSE (demonstrated here) and scrapie (previously reported) support the view that 
the K222 PRNP variant is a good candidate for improving breeding programs to control 
and eradicate TSEs in goats. IC inoculations of prions in Tg mouse models expressing 
different PRNP polymorphic variants are highly valuable to determine the role of PRNP 
amino acid exchanges in the conversion capacity of host PrPC although this kind of 
procedure doesn´t always predict the genotype-dependent susceptibility of host species 
to natural prion infection. Therefore, prion transmission studies in the natural host using 
the natural route of infection (as presented in this study) are necessary to conclude at 
this point. 
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FIGURE LEGENDS 
Figure 1. Brain PrPres from wild type (WT) and R/Q211 goats orally inoculated with a 
goat-BSE isolate. Immunoblots of brain PrPres detected with Sha31 mAb. Identical 
amounts of 10% brain homogenate were loaded in each lane. The original Goat-BSE 
isolate (gBSE-P12) used for goat inoculations was also included in the blot (Goat-BSE). 
Molecular weights (in kDa) are shown at the right side of the blot. 
Figure 2. Brain PrPres detected in BoPrP-Tg110 mice inoculated with different goat 
tissues homogenates. Immunoblots of PrPres in BoPrP-Tg110 mice inoculated with 
different tissue homogenates from ZG01 WT (R211Q222/RQ) goat; ZG28, ZG05 and 
ZG20 R/Q211 goats (pooled homogenates) and ZG11 Q/K222 goat. Similar quantities of 
PrPres were loaded for adequate comparison and immunoblots were detected with Sha31 
mAb. The original goat-BSE isolate (gBSE-P12) used for goat inoculations was also 
included in the blot (Goat-BSE). Molecular weights (in kDa) are shown at the right side 
of the blot.  
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Table 1:  Clinical sign evaluation and PrPSc detection in tissues of wild type 
(R211Q222/RQ), R/Q211 and Q/K222 PRNP goats orally challenged with a Goat-BSE 
isolate and sequentially culled 
PRNP 
genotype Goat code 
Endpoint 
(mpi)* 
Clinical 
signs Goat tissue 
PrPSc ** 
WB IHC   PTA-WB 
WT+ 
 
ZG26 6 - 
Brain - - - 
Psoas major muscle - ND*** ND 
Retractor bulbi muscle - ND ND 
Popliteal lymphonode - ND ND 
ZG32 6 - 
Brain - - - 
Psoas major muscle - ND ND 
Retractor bulbi muscle - ND ND 
Popliteal lymphonode - ND ND 
ZG35 6 - 
Brain - - - 
Psoas major muscle - ND ND 
Retractor bulbi muscle - ND ND 
Popliteal lymphonode - ND ND 
ZG19 12 - 
Brain - - - 
Psoas major muscle - ND ND 
Retractor bulbi muscle - ND ND 
Popliteal lymphonode - ND ND 
ZG24 12 - 
Brain - - - 
Psoas major muscle - ND ND 
Retractor bulbi muscle - ND ND 
Popliteal lymphonode - ND ND 
ZG30 12 - 
Brain - - - 
Psoas major muscle - ND ND 
Retractor bulbi muscle - ND ND 
Popliteal lymphonode - ND ND 
ZG01 24 + 
Brain + + + 
Psoas major muscle - - ND 
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Retractor bulbi muscle - - ND 
Popliteal lymphonode - - ND 
R/Q211 
 
ZG13 24 - Brain - - - 
ZG28 33 + 
Brain + + + 
Psoas major muscle - - ND 
Retractor bulbi muscle - - ND 
Popliteal lymphonode - - ND 
ZG05 34 + 
Brain + + + 
Psoas major muscle - - ND 
Retractor bulbi muscle - - ND 
Popliteal lymphonode - - ND 
 
ZG20 36 + 
Brain + + + 
Psoas major muscle - - ND 
Retractor bulbi muscle - - ND 
Popliteal lymphonode - - ND 
Q/K222 
 
ZG10 24 - Brain - - - 
ZG25 44 - 
Brain - - - 
Psoas major muscle - - ND 
Popliteal lymphonode - - ND 
ZG11       45 
 Brain - - - 
Psoas major muscle - - ND 
 Popliteal lymphonode - - ND 
+ Goat wild type PRNP genotype: R211Q222/RQ 
* mpi: months post-inoculation 
** Abnormal prion protein (PrPSc) determined by Western-blot (WB), 
immunohistochemistry (IHC) or phosphotungstic acid Western-blot (PTA-WB) 
*** Not determined  
 
 at The U
niversity of Edinburgh on February 27, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
Table 2: Infectious titer in tissues from Goat-BSE orally inoculated WT, R/Q211 and 
Q/K222 PRNP goats as determined by mouse bioassay 
PRNP 
genotype 
Goat codes of 
pooled tissues 
Endpoint 
(mpi)* 
Goat  tissue 
Mouse bioassay in BoPrP-Tg110 
mice 
MST±SEM 
(n/n0)** 
Infectious titer***
WT+ 
ZG26-ZG32-
ZG35 
 
6 
Brain 650 (0/6) -**** 
Psoas major muscle 650 (0/6) - 
Popliteal lymphonode 650 (0/6) - 
ZG19-ZG24-
ZG30 
 
12 
Brain 650 (0/6) - 
Psoas major muscle 650 (0/6) - 
Popliteal lymphonode 650 (0/6) - 
ZG01 
 
24 
Brain 261±20 (6/6) +++ 
Psoas major muscle 596, 598 (2/6) - 
Retractor bulbi muscle 469±29 (3/6) - 
Popliteal lymphonode 526 (1/6) - 
R/Q211 
ZG13 24 Brain 650 (0/6) - 
ZG28-ZG05-
ZG20 
 
33-34-36 
Brain 258±15 (6/6) +++ 
Psoas major muscle 334±24 (6/6) ++ 
Retractor bulbi muscle 307±84 (5/5) ++ 
Popliteal lymphonode 406±50 (2/4) + 
Q/K222 
ZG10 24 Brain 650 (0/6) - 
ZG25 
 
44 
Brain 650 (0/6) - 
Psoas major muscle 550 (1/6) - 
Popliteal lymphonode 650 (0/6) - 
ZG11 45 
Brain 400±50 (6/6) + 
Psoas major muscle 522 (1/6) - 
Popliteal lymphonode 650 (0/6) - 
+ Goat wild type PRNP genotype: R211Q222/RQ. 
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* mpi:months post-inoculation. 
** Mean Survival Time in days ± Standard error of the mean (n/n0: diseased, PrPres 
positive/inoculated animals). 
*** Infectious titer of each goat tissue was calculated as a function of the survival times 
obtained after their inoculation in BoPrP-Tg110 mice and expressed as ID per grams of 
the inoculated tissue (ID/g) (see supplemental data). Infectious titers of the goat tissues 
were scored as - when they were lower than the limit of detection of the mouse bioassay 
calculated by the Reed-Muench method [29] (5x 102 ID/g); + when they ranged from 5x 
102 ID/g to 5x 104 ID/g; ++ when they ranged from >5x 104 ID/g to 5x 106 ID/g, and 
+++ when they were higher than 5x 106 ID/g. 
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